Browsing items tagged “Japan | EVERSANA”

Japan Pharma Association Introduces Bold Policy Measures to Reform Sector

Country: JAPAN | Region: ASIA & SOUTH PACIFIC | Type: Policy | Keywords: #covid19 #drugsupply #innovation #jpma #marketentryrewards #mhlw #patientaccess #pharmasector #r&d #re-pricing #regulation #taxincentives #vaccines PRICENTRIC BRIEF: The Japan Pharmaceutical Manufacturers Association (JPMA) has proposed a new policy for economic and fiscal management and reform in Japan, which was mainly inspired by the effect of the coronavirus pandemic on the healthcare system and pharmaceutical industry in Japan The proposal first addresses the immediate need of […]

Zolgensma Proposed to Cost 167 Million Yen in Japan

Country: JAPAN | Region: ASIA & SOUTH PACIFIC | Type: Pricing & Reimbursement | Keywords: #chuikyo #genetherapy #listing #mhlw #nhi #novartis #pediatrics PRICENTRIC BRIEF: Japanese media have reported that the price of Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec) is expected to be 167 million yen under the National Health Insurance (NHI) scheme In the case of Zolgensma, health official insiders from the MHLW suggested that the […]

Japan’s PMDA Evaluates Side Effects of Insulins, Cancer Drugs

Country: JAPAN | Region: ASIA & SOUTH PACIFIC | Type: Regulation | Keywords: #astrazeneca #cancer #elililly #insulin #janssen #novonordisk #pmda #sideeffects PRICENTRIC BRIEF: Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) is currently investigating new side effect risks for 15 insulins and two cancer drugs The PMDA is examining risks associated with Eli Lilly’s Humalog/Lyumjev (insulin lispro) and Novo Nordisk’s Xultophy (insulin degludec + liraglutide) and Fiasp (insulin aspart) Also under review […]

Daiichi Sankyo Submits Yescarta NDA to Japan MHLW

Country: JAPAN | Region: ASIA & SOUTH PACIFIC | Type: Drug Approval | Keywords: #cartcelltherapy #cellandgenetherapy #daiichisankyo #genetherapy #gilead #kite #lymphoma #mhlw #newdrugapplication PRICENTRIC BRIEF: Daiichi Sankyo has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labor, and Welfare (MHLW) for its CAR T-cell therapy Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed/refractory (R/R) diffused large B-cell lymphoma (DLBCL) and related lymphomas The NDA for […]